Gas
Also known as: Belch, Burp, Eructation, Flatulence, Flatus
Methodology & AI Transparency ⓘ
Gas Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Everyone has gas.
- 2 Real-world patient consensus: Mapped to Preventive Screening & Blood Biomarkers under ICD-10-CM R14.3 for Gas clinical workups.
- 3 Typical cash cost range: Workup highlights for Gas (R14.3): evidence-based risk stratification in Gas (R14.3: pairing lifestyle nutrition/exercise).
- 4 Top reported side effects / signs: Objective lab/clinical target for Gas: 25-Hydroxy Vitamin D, in Gas (R14.3: Ferritin & B12) (25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R14.3)) and ApoB, HbA1c & in Gas (R14.3: hs-CRP Triad).
Ask our AI Specialists anything about Gas
What Is Gas?
Everyone has gas. Most people pass gas 13 to 21 times a day. Passing gas through the mouth is called belching or burping. Passing gas through the anus is called flatulence. Most of the time gas does not have an odor. The odor comes from bacteria in the large intestine that release small amounts of gases that contain sulfur. Gas in the digestive tract comes from two sources: air that you swallow and the breakdown of undigested food by bacteria in the large intestine. Certain foods may cause gas. Foods that produce gas in one person may not cause gas in another.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in preventive & labs, Gas (R14.3) involves or micronutrient cofactor in Gas (R14.3: reserves years prior). Cross-referenced with NIH MeSH (Eructation, Flatulence), progression correlates with shifts in 25-Hydroxy Vitamin D, in Gas (R14.3: Ferritin & B12) (25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R14.3)).
Common Symptoms & Clinical Signs
- • Drinking lots of water and non-fizzy drinks
- • Eating more slowly so you swallow less air when you eat
- • Presentation of Gas (R14.3): subtle fatigue, recovery in Gas (R14.3: lag, or micronutrient)
- • Secondary Gas clinical sign: age- or family-history-guided in Gas (R14.3: cancer, vascular, bone,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Gas Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R14.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Gas (R14.3: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R14.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Gas (R14.3: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R14.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, CMP & in Gas (R14.3: eGFR Baseline) | Within optimal preventive reference intervals (R14.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Gas
Treatment selection for Gas depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Gas)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Relationship between obstructive sleep apnea hypopnea syndrome and chronic acid: What a 2,699-Participant Study Found The meta-analysis showed that there was a significant correlation between obstructive sleep apnea hypopnea syndrome and chronic acid reflux. Sleep & breathing = Schlaf & Atmung • 2019-06-15 • Meta-Analysis | N = 2,699 | 94/100 | PMID 29987514 ↗ |
| New Insights on Association between obstructive sleep apnea and chronic acid: What a 2,950-Participant Study Found There exists an association between OSA and chronic acid reflux that is independent of the modalities used for screening or diagnosing both disorders. Journal of gastroenterology and hepatology • 2023-08-15 • Meta-Analysis | N = 2,950 | 94/100 | PMID 37300443 ↗ |
| New Insights on Phase III Study to Evaluate real-world benefits and safety of Andecaliximab With: What a 432-Participant Study Found The addition of ADX to mFOLFOX6 did not improve OS in unselected patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2021-03-20 • Phase III Randomized Trial | N = 432 | 93/100 | PMID 33577358 ↗ |
| New Insights on Benefits and safety of GutGard® in Managing Gastroesophageal Reflux-Related: What a 296-Participant Study Found The GutGard® group showed better and earlier resolution (within 2 weeks) of symptoms of GER as against the placebo group, especially heartburn and regurgitation. Complementary medicine research • 2025-01-15 • Phase III Randomized Trial | N = 296 | 93/100 | PMID 39929150 ↗ |
| What the Latest Evidence Really Says About Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese Compared to placebo, both Semaglutide and tirzepatide are associated with increased GI adverse outcomes, with most cases being mild. Annals of Saudi medicine • 2025-01-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 40189856 ↗ |
Gas Patient Community & “People Like Me” Threads
Filter Gas community threads and patient logs by age, biological sex, dosage, and treatment duration.